says that he remembers how people survived or fought in Silo by using hidden pathways. The memory of his guilt regarding what had happened widens the emotional dimension of the exploration of such ...

Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced a positive update ...

Both SPC-15 and SP-26 may qualify for the FDA’s streamlined 505(b)(2) regulatory pathway, which could expedite their approval processes. Silo is collaborating with esteemed research institutions ...

No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the ...

Delivered via an intranasal formulation, SPC-15 may qualify for the FDA's streamlined 505(b)(2) regulatory pathway, potentially accelerating its approval process. Currently, Silo Pharma is ...